Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome

Expert Opinion on Drug Discovery

Volumn 4, Issue 3, 2009, Pages 219-227

  Cornet, Alexander D ^a   Van Nieuw Amerongen, Geerten P ^a,b   Beishuizen, Albertus ^a   Schultz, Marcus J ^c   Girbes, Armand R J ^a   Groeneveld, A B Johan ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ALI ARDS; aPC; Endothelial barrier function; EPCR; PAR 1; Permeability

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; PLACEBO;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLOOD CLOTTING; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMPETITIVE INHIBITION; DRUG EFFECT; ENDOTHELIUM; FIBRINOLYSIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; MEDLINE; META ANALYSIS; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW;

EID: 67649183649     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440902721204     Document Type: Review

References (98)

1. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-1693 (Pubitemid 41464707)
2. Wind J, Versteegt J, Twisk J, et al. Epidemiology of acute lung injury and acute respiratory distress syndrome in The Netherlands: a survey. Respir Med 2007;101:2091-2098 (Pubitemid 47324255)
3. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301-1308
4. Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med 2006;21:119-143
5. Groeneveld ABJ. Vascular pharmacology of acute lung injury and acute respiratory distress syndrome. Vascul Pharmacol 2002;39:247-256 (Pubitemid 37490750)
6. Piantadosi CA, Schwartz DA. The acute respiratory distress syndrome. Ann Intern Med 2004;141:460-470 (Pubitemid 39281882)
7. Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164:1896-1903 (Pubitemid 33152327)
8. Budinger GRS, Sznajder JI. The alveolar-epithelial barrier: a target for potential therapy. Clin Chest Med 2006;27:655-669 (Pubitemid 44666249)
9. Maniatis NA, Orfanos SE. The endothelium in acute lung injury/acute respiratory distress syndrome. Curr Opin Crit Care 2008;14:22-30
10. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004;109:2698-2704 (Pubitemid 38737913)
11. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003;7:23-38 (Pubitemid 36204267)
12. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - a review. Crit Care Med 2006;34:871-877 (Pubitemid 43308283)
13. Gunther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;161:454-462 (Pubitemid 30129452)
14. Ware LB, Matthay MA, Parsons PE, et al. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007;35:1821-1828 (Pubitemid 47220354)
15. Choi G, Hofstra JJ, Roelofs JJTH, et al. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007;35:1362-1368 (Pubitemid 46642667)
16. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008;178:618-623
17. van der Poll T, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005;171:1125-1128 (Pubitemid 40663724)
18. Waerhaug K, Kuklin VN, Kirov MY, et al. Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep. Crit Care 2008;12:R104
19. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;285:L514-21 (Pubitemid 37022850)
20. Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 2001;91:1487-1500 (Pubitemid 32900340)
21. van Nieuw Amerongen GP, Musters RJP, Eringa EC, et al. Thrombin-induced endothelial barrier disruption in intact microvessels: role of RhoA/Rho kinase-myosin phosphatase axis. Am J Physiol Cell Physiol 2008;294:C1234-41
22. Garcia JG, Liu F, Verin AD, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 2001;108:689-701 (Pubitemid 32906197)
23. Tauseef M, Kini V, Knezevic N, et al. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1- phosphate receptor signaling in endothelial cells. Circ Res 2008;103:1164-1172
24. Wang L, Dudek SM. Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res 2008 [Epub ahead of print]
25. Yatomi Y, Ohmori T, Rile G, et al. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 2000;96:3431-3438 (Pubitemid 30836322)
26. Kaneider NC, Leger AJ, Agarwal A, et al. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007;8:1303-1312
27. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709 (Pubitemid 32204987)
28. Marti-Carvajal A, Salanti G, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2008;CD004388
29. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007;204:2439-2448 (Pubitemid 47529328)
30. Cornet AD, Beishuizen A, Groeneveld ABJ. Activated protein C in sepsis: tightening pulmonary endothelial cells? Crit Care Med 2007;35:2656-2658
31. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007;109:3161-3172 (Pubitemid 46572500)
32. Wang L, Bastarache JA, Wickersham N, et al. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 2007;36:497-503 (Pubitemid 46623009)
33. Toltl LJ, Beaudin S, Liaw PC. Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. J Immunol 2008;181:2165-2173
34. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996;88:2093-2100 (Pubitemid 26307911)
35. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002;296:1880-1882 (Pubitemid 34596276)
36. Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199-11203 (Pubitemid 38089304)
37. Franscini N, Bachli EB, Blau N, et al. Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation 2004;110:2903-2909 (Pubitemid 39473616)
38. Brueckmann M, Horn S, Lang S, et al. Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1. Thromb Haemost 2005;93:743-750 (Pubitemid 40485413)
39. Dubniks M, Grande PO. The effects of activated protein C and prostacyclin on arterial oxygenation and protein leakage in the lung and the gut under endotoxaemia in the rat. Acta Anaesthesiol Scand 2008;52:381-387 (Pubitemid 351207960)
40. Hooper WC, Phillips DJ, Renshaw MA, et al. The up-regulation of IL-6 and IL-8 in human endothelial cells by activated protein C. J Immunol 1998;161:2567-2573 (Pubitemid 28397075)
41. Neumann FJ, Ott I, Marx N, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997;17:3399-3405 (Pubitemid 28028548)
42. Hechtman DH, Cybulsky MI, Fuchs HJ, et al. Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol 1991;147:883-892
43. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101:311-320 (Pubitemid 28067327)
44. Kirschenbaum LA, Lopez WC, Ohrum P, et al. Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock. Crit Care Med 2006;34:2207-2212 (Pubitemid 44305627)
45. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004;104:3878-3885 (Pubitemid 39620133)
46. Slofstra SH, Groot AP, Maris NA, et al. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 2006;149:740-746 (Pubitemid 44748066)
47. Sturn DH, Kaneider NC, Feistritzer C, et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003;102:1499-1505 (Pubitemid 36988062)
48. Choi G, Vlaar APJ, Schouten M, et al. Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 2007;30:423-428 (Pubitemid 351182063)
49. Kotanidou A, Loutrari H, Papadomichelakis E, et al. Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascul Pharmacol 2006;45:134-140 (Pubitemid 44374413)
50. Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997;272: L197-202 (Pubitemid 27137258)
51. Richard JC, Bregeon F, Leray V, et al. Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury. Intensive Care Med 2007;33:2199-2206 (Pubitemid 350164548)
52. Tanaka A, Minoguchi K, Chen X, et al. Activated protein C attenuates leukocyte elastase-induced lung injury in mice. Shock 2008;30:153-158
53. Teke Z, Sacar M, Yenisey C, et al. Activated protein C attenuates intestinal reperfusion-induced acute lung injury: an experimental study in a rat model. Am J Surg 2008;195:861-873 (Pubitemid 351749444)
54. Dahlen SE, Bjork J, Hedqvist P, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 1981;78:3887-3891 (Pubitemid 11060581)
55. Brueckmann M, Hoffmann U, De Rossi L, et al. Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine 2004;26:106-113 (Pubitemid 38596920)
56. Pereira C, Schaer DJ, Bachli EB, et al. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol 2008;28:504-510
57. Jian MY, Koizumi T, Tsushima K, et al. Activated protein C attenuates acid-aspiration lung injury in rats. Pulm Pharmacol Ther 2005;18:291-296 (Pubitemid 40379752)
58. Pirrone F, Mazzola SM, Pastore C, et al. Activated protein C protection from lung inflammation in endotoxin-induced injury. Exp Biol Med (Maywood) 2008;233:1462-1468
59. Wong SS, Sun NN, Hyde JD, et al. Drotrecogin alfa (activated) prevents smoke-induced increases in pulmonary microvascular permeability and proinflammatory cytokine IL-1beta in rats. Lung 2004;182:319-330 (Pubitemid 40685143)
60. Bannerman DD, Goldblum SE. Mechanisms of bacterial lipopolysaccharide- induced endothelial apoptosis. Am J Physiol Lung Cell Mol Physiol 2003;284: L899-914 (Pubitemid 36687124)
61. Bilbault P, Lavaux T, Launoy A, et al. Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. Crit Care Med 2007;35:69-75 (Pubitemid 46035679)
62. O'Brien LA, Richardson MA, Mehrbod SF, et al. Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an. Arterioscler Thromb Vasc Biol 2007;27:2634-2641
63. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003;9:338-342 (Pubitemid 36362790)
64. Liu D, Cheng T, Guo H, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004;10:1379-1383 (Pubitemid 40022721)
65. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003;373:65-70 (Pubitemid 36819502)
66. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005;280:17286-17293 (Pubitemid 41389197)
67. Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007;110:3909-3916 (Pubitemid 350248446)
68. Bae JS, Rezaie AR. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 2008;100:101-109 (Pubitemid 351948751)
69. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005;105:3178-3184 (Pubitemid 40504337)
70. Feistritzer C, Schuepbach RA, Mosnier LO, et al. Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem 2006;281:20077-20084 (Pubitemid 44065782)
71. Singleton PA, Dudek SM, Chiang ET, Garcia JGN. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J 2005;19:1646-1656 (Pubitemid 41429522)
72. van Nieuw Amerongen GP, van Hinsbergh VWM. Endogenous RhoA inhibitor protects endothelial barrier. Circ Res 2007;101:7-9 (Pubitemid 47094618)
73. Ludeman MJ, Kataoka H, Srinivasan Y, et al. PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem 2005;280:13122-13128 (Pubitemid 40491136)
74. Riewald M, Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem 2005;280:19808-19814 (Pubitemid 41379506)
75. Schuepbach RA, Feistritzer C, Brass LF, Riewald M. Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood 2008;111:2667-2673
76. Murakami K, Okajima K, Uchiba M, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87:642-647 (Pubitemid 26030319)
77. Wang Z, Su F, Rogiers P, Vincent JL. Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 2007;35:2594-2600 (Pubitemid 351339022)
78. Velik-Salchner C, Wenzel V, Maybauer DM, Maybauer MO. Recombinant human activated protein C in experimental models of acute lung injury: the timing is critical! Intensive Care Med 2007;33:2048-2050
79. Looney MR, Esmon CT, Matthay MA. The role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury in mice. Thorax 2008 [Epub ahead of print]
80. Robriquet L, Collet F, Tournoys A, et al. Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res 2006;7:41
81. Choi G, Hofstra JJ, Roelofs JJTH, et al. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008;36:204-210
82. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-1341 (Pubitemid 41362701)
83. Finfer S, Ranieri VM, Thompson BT, et al. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008;34:1935-1947
84. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369:836-843 (Pubitemid 46365900)
85. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31:12-19 (Pubitemid 36151143)
86. Laterre PF, Levy H, Clermont G, et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med 2004;32:2207-2218 (Pubitemid 39491799)
87. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005;33:952-961 (Pubitemid 40638163)
88. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;31:834-840 (Pubitemid 36379592)
89. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005;33:2266-2277 (Pubitemid 41437481)
90. Vincent JL, O'Brien JJ, Wheeler A, et al. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 2006;10:R74 (Pubitemid 47086851)
91. Available from: http://www.trialregister.nl/trialreg/admin/rctview.asp? TC=745
92. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-1349 (Pubitemid 30408719)
93. Gupta A, Rhodes GJ, Berg DT, et al. Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. Am J Physiol Renal Physiol 2007;293: F245-F254 (Pubitemid 47345024)
94. Scaldaferri F, Sans M, Vetrano S, et al. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest 2007;117:1951-1960 (Pubitemid 47036329)
95. Li SS. To be or not to be protease activated receptor-1 in activated protein C-initiated endothelial barrier protection? Crit Care 2007;11:407
96. Esmon CT. Is APC activation of endothelial cell PAR1 important in severe sepsis?: No. J Thromb Haemost 2005;3:1910-1911 (Pubitemid 43086042)
97. Ruf W. Is APC activation of endothelial cell PAR1 important in severe sepsis?: Yes. J Thromb Haemost 2005;3:1912-1914 (Pubitemid 43086043)
98. Maybauer MO, Maybauer DM, Fraser JF, et al. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Crit Care Med 2006;34:2432-2438 (Pubitemid 44262031)